Spinal zap trial aims to help SMA patients move better

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject or subject's parent or legal guardian (for minor subjects) has provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures. Minor subjects will be asked to give written assent according to local requirements. 2. Subject has a diagnosis of 5q-autosomal recessive SMA confirmed by determination of a genetic deletion in the SMN1 gene (5q12.2-q13.3) 3. Subject is diagnosed as having Type 3 or Type 4 SMA based on the following criteria 1. Disease manifested after 18 months of age 2. Disease manifested after ambulation was acquired 4. Subject is ≥16 years of age and \< 65 years of age 5. Subject is able to stand independently for ≥3 seconds 6. RHS score lower or equal to 65 7. Subject (and subject's parent or legal guardian if subject is a minor) is willing and able to comply with scheduled visits and study procedures Exclusion Criteria: 1. Subject has deformation of the spinal canal preventing lead implantation as judged by the study neurosurgeon 2. Subject has size of spinal canal that is insufficient for lead implantation as judged by the study neurosurgeon 3. Subject has moderate or severe joint contractures that would affect ability to perform study measures 4. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator 5. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety of anesthesia or the procedures, make it unlikely that intervention or follow-up will be correctly completed or impair the assessment of study results, in the opinion of the investigator 6. Female subjects are pregnant or breastfeeding 7. Subject has severe claustrophobia 8. Subject is on anticoagulant, anti-spasticity or anti-seizure medication within 4 weeks of lead implantation or requires these medications during the treatment phase of the study 9. Subject has medical implant that precludes magnetic resonance imaging